Efficacy of Ateplase and Recombinant Streptokinase in Emergency ST Elevation Myocardial Infarction
阿替普酶与重组链激酶用于急诊ST段抬高型心肌梗死的疗效研究

摘要

目的 观察急诊在对ST段抬高型心肌梗死患者进行治疗时选择阿替普酶与重组链激酶进行治疗的效果。方法 结合对比治疗观察的方式开展探究，纳入在2021年2月至2022年6月收治患者86例为对象，双盲法均分为对照组（43例，使用阿替普酶开展治疗）和观察组（43例，以重组链激酶进行治疗）。分析两组患者的恢复情况。结果 对比两组患者在治疗后60分钟、90分钟以及120分钟血管再通率，观察组均显著高于对照组，P<0.05。统计两组恢复期间不良反应情况，观察组发生率低于对照组，P<0.05。统计两组ST段抬高改善时间以及胸痛症状改善时间，观察组用时均短于对照组，P<0.05。结论 在对急诊ST段抬高型心肌梗死患者进行治疗中选择阿替普酶进行治疗，可以保障患者血管再通率，并降低不良反应发生率，缩短患者症状改善用时，效果好于重组链激酶。

Abstract

Objective To observe the effect of Ateplase and recombinant streptokinase in emergency treatment of patients with ST segment elevation myocardial infarction.
Methods Combined with the way of comparative treatment and observation, 86 patients were included in the study from February 2021 to June 2022. Double blind method was used to divide them into the control group (43 patients were treated with alteplase) and the observation group (43 patients were treated with recombinant streptokinase). The recovery of the two groups of patients was analyzed.
Results Compared with the control group, the vascular recanalization rate in the observation group was significantly higher than that in the control group at 60 minutes, 90 minutes and 120 minutes after treatment, P<0.05. The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). Statistics showed that the improvement time of ST segment elevation and chest pain symptoms in the two groups were shorter than those in the control group (P<0.05).
Conclusion   In the treatment of emergency patients with ST segment elevation myocardial infarction, selecting ateplase for treatment can ensure the patients' vascular recanalization rate, reduce the incidence of adverse reactions, shorten the time for patients to improve their symptoms, and the effect is better than that of recombinant streptokinase.